Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Bristol Myers Updates Action Date for Subcutaneous Opdivo

Published 23/05/2024, 17:49
Bristol Myers Updates Action Date for Subcutaneous Opdivo
BMY
-

Benzinga - by Zacks, Benzinga Contributor.

Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.

The subcutaneous formulation of Opdivo is co-formulated with Halozyme's proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all previously approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.

The BLA was accepted earlier this month with a target action date of Feb 28, 2025.

The application is based on results from the phase III CheckMate -67T study evaluating subcutaneous administration of Opdivo co-formulated with rHuPH20 compared to intravenous Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.

Per BMY, this is the first phase III study of the subcutaneous formulation of nivolumab to evaluate and demonstrate non-inferior pharmacokinetics, efficacy and consistent safety vis-a-vis its intravenous formulation (IV). The subcutaneous formulation has the potential to be the first and only subcutaneously administered PD-1 inhibitor upon potential approval.

The formulation provides physicians with the improved convenience of an injection administered in three to five minutes rather than a 30 to 60-minute infusion. The safety profile of subcutaneous nivolumab was consistent with the IV formulation.

The company's shares have lost 17.6% year to date compared with the industry's decline of 5.2%.

Image Source: Zacks Investment Research

Opdivo is one of the top drugs for BMY. Earlier in the month, BMY announced that a late-stage study seeking to expand the label of Opdivo in combination with Yervoy failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer.

Approval of new drugs and label expansion of existing ones are important for BMY as the company looks to expand its portfolio. Bristol-Myers reported better-than-expected first-quarter results, as adjusted loss was narrower than expected and sales beat estimates. However, the decline in Opdivo sales was a dampener.

One of the top drugs, Revlimid, is already facing generic competition, and Eliquis, too, is likely to face challenges later.

Hence, BMY is banking on Opdivo and newer drugs like Reblozyl and Opdualag to drive growth in the future.

The recent acquisitions of Mirati Therapeutics, Karuna Therapeutics, Inc., and RayzeBio should aid the company's cause, too.

Concurrent with the first-quarter earnings release, Bristol Myers also announced that it is undertaking a strategic productivity initiative that will drive approximately $1.5 billion in cost savings by the end of 2025.

Zacks Rank & a Stock to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold).

A couple of better-ranked stocks from the healthcare industry are Ligand Pharmaceuticals (NASDAQ: LGND) and ALX Oncology Holdings (NASDAQ: ALXO). Both the stocks carry a Zacks Rank #2 (Buy) each at present.

In the past 30 days, the Zacks Consensus Estimate for Ligand's 2024 and 2025 earnings per share has remained constant at $4.56 and $5.20, respectively. Shares of LGND are up 22% year to date.

In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.

ALX Oncology beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 8.83%.

To read this article on Zacks.com click here.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.